◆英語タイトル:Vexim SA - Product Pipeline Analysis, 2018 Uate
◆商品コード:DATA904C12532
◆発行会社(調査会社):
GlobalData
◆発行日:2018年12月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controlled anatomical restoration include biomaterials, cement mixing systems, 3D mapping software, and others. Vexim’s advanced vertebroplasty therapy solutions offer a high-pressure injector for use with mixer that is specifically adapted to high viscosity cement. The company uses 3D reconstruction technique to evaluate the anatomical restoration in a clear and accurate way. Vexim is headquartered in Toulouse, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Vexim SA
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Vexim SA Company Overview 4
Vexim SA Company Snapshot 4
Vexim SA Pipeline Products and Ongoing Clinical Trials Overview 4
Vexim SA – Pipeline Analysis Overview 6
Vexim SA – Key Facts 6
Vexim SA – Major Products and Services 7
Vexim SA Pipeline Products by Development Stage 8
Vexim SA Ongoing Clinical Trials by Trial Status 10
Vexim SA Pipeline Products Overview 12
Implant Imagery Software 12
Implant Imagery Software Product Overview 12
SpineJack Implant 13
SpineJack Implant Product Overview 13
SpineJack Implant Clinical Trial 14
SpineJack Implant – 4.2 mm Diameter Model 15
SpineJack Implant – 4.2 mm Diameter Model Product Overview 15
SpineJack Implant – 6.5 mm Diameter Model 16
SpineJack Implant – 6.5 mm Diameter Model Product Overview 16
Vexim SA – Key Competitors 17
Vexim SA – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Vexim SA, Recent Developments 19
Jan 12, 2018: VEXIM: +17% Growth in Sales in 2017 up to €21.6 Million 19
Jul 11, 2017: VEXIM: Continued Growth and Adoption of the SpineJack in Q2 2017 19
May 29, 2017: VEXIM: ANVISA Approves SpineJack Implants in Brazil 19
Apr 19, 2017: VEXIM: Continued sales growth in Q1 2017 20
Apr 18, 2017: VEXIM: New Product Launch in Germany: MASTERFLOW PLUS, a New Product Targeted at Low Energy Osteoporotic Fractures 20
Oct 13, 2016: VEXIM: +37% sales increase to €13.3 million as of September 30, 2016 (9 months) 21
Mar 10, 2015: VEXIM Obtains CE Approval to Market Masterflow Injection System in Europe 21
Feb 19, 2015: VEXIM Announces Successful GMP Inspection by Brazil’s National Health Surveillance Agency 21
Jan 26, 2015: VEXIM 2014 sales increase sharply by 69% to €10.3 million 22
Dec 10, 2014: Vexim Obtains FDA Approval To Market Masterflow Injection System In the United States 22
Appendix 24
Methodology 24
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Vexim SA Pipeline Products and Ongoing Clinical Trials Overview 4
Vexim SA Pipeline Products by Equipment Type 5
Vexim SA Pipeline Products by Indication 5
Vexim SA Ongoing Clinical Trials by Trial Status 5
Vexim SA, Key Facts 6
Vexim SA, Major Products and Services 7
Vexim SA Number of Pipeline Products by Development Stage 8
Vexim SA Pipeline Products Summary by Development Stage 9
Vexim SA Ongoing Clinical Trials by Trial Status 10
Vexim SA Ongoing Clinical Trials Summary 11
Implant Imagery Software - Product Status 12
Implant Imagery Software - Product Description 12
SpineJack Implant - Product Status 13
SpineJack Implant - Product Description 13
SpineJack Implant - Prospective Multicenter Randomized Study Comparing Two Standard Treatments: SpineJack System and Conservative Orthopedic Management in Acute Traumatic Vertebral Fractures Types A1 and A3.1 According to the Magerl Classification 14
SpineJack Implant - 4.2 mm Diameter Model - Product Status 15
SpineJack Implant - 4.2 mm Diameter Model - Product Description 15
SpineJack Implant - 6.5 mm Diameter Model - Product Status 16
SpineJack Implant - 6.5 mm Diameter Model - Product Description 16
Vexim SA, Subsidiaries 18
Glossary 26
List of Figures
Vexim SA Pipeline Products by Equipment Type 5
Vexim SA Pipeline Products by Development Stage 8
Vexim SA Ongoing Clinical Trials by Trial Status 10